# The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients

> **NCT05680870** · PHASE3 · COMPLETED · sponsor: **Aya Mohamed Sadek Elsaid** · enrollment: 46 (actual)

## Conditions studied

- Chemotherapy Induced Peripheral Neuropathy

## Interventions

- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT05680870
- **Lead sponsor:** Aya Mohamed Sadek Elsaid
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-01
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05680870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05680870, "The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05680870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*